Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Homospisulosine (KP7) is a synthetic analog of **spisulosine** (1-deoxysphinganine), a sphingoid amino alcohol originally isolated from the sea clam *Spisula polynyma*. While the parent compound spisulosine demonstrated potent antiproliferative activity against a broad spectrum of solid tumors in early clinical trials, its development was hindered by significant neurotoxicity. Homospisulosine was developed as a derivative to maintain anticancer efficacy while potentially improving the therapeutic window. Preclinical studies in cervical carcinoma (HeLa) cells have shown that homospisulosine induces apoptosis through the mitochondrial pathway, evidenced by the dissipation of mitochondrial membrane potential, activation of **caspase-3**, and cleavage of **PARP**. Additionally, it has been observed to increase the levels of the cell cycle inhibitor **p27** and modulate **Bcl-2** through phosphorylation at the Ser70 residue.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on homospisulosine.